Compare Stocks

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRA Biofrontera	$2.60	$2.95	$2.09 ▼ $7.54	$73.73M	1.02	27,512 shs	7,263 shs
EVFM Evofem Biosciences	$0.02 +12.8%	$0.02	$0.01 ▼ $4.05	$858K	-1.12	780,007 shs	208,963 shs
NBSE NeuBase Therapeutics	$0.41 -5.2%	$0.71	$0.39 ▼ $4.80	$1.54M	0.83	208,617 shs	10,489 shs
OPTN OptiNose	$0.94 +1.3%	$1.51	$0.90 ▼ $2.10	$105.90M	-0.24	531,023 shs	274,117 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRA Biofrontera	0.00%	0.00%	0.00%	0.00%	0.00%
EVFM Evofem Biosciences	+3.68%	-11.04%	-21.23%	-64.12%	-99.64%
NBSE NeuBase Therapeutics	+1.07%	+3.49%	-58.80%	-30.76%	-88.21%
OPTN OptiNose	-9.05%	-25.19%	-46.06%	-31.79%	-52.67%

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	3.0803 of 5 stars	3.5	3.0	0.0	4.2	0.0	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRA Biofrontera	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	2.00	Hold	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A
OPTN OptiNose	3.00	Buy	$4.00	325.49% Upside

Current Analyst Ratings

Latest OPTN, BFRA, EVFM, and NBSE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/18/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/18/2024	OPTN OptiNose	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $4.00
3/11/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$5.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRA Biofrontera	$36.19M	2.04	N/A	N/A	$0.35 per share	7.43
EVFM Evofem Biosciences	$18.22M	0.05	$1.59 per share	0.01	($2.64) per share	-0.01
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	$11.04 per share	N/A
OPTN OptiNose	$70.99M	1.49	N/A	N/A	($0.77) per share	-1.22

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRA Biofrontera	-$14.88M	-$0.73	N/A	∞	N/A	-59.44%	-93.31%	-24.02%	N/A
EVFM Evofem Biosciences	$52.98M	-$7.62	N/A	∞	N/A	290.81%	-90.20%	331.20%	4/26/2024 (Estimated)
NBSE NeuBase Therapeutics	-$4.37M	-$7.70	N/A	∞	N/A	N/A	-99.74%	-60.13%	5/9/2024 (Estimated)
OPTN OptiNose	-$35.48M	-$0.32	N/A	N/A	N/A	-50.06%	N/A	-33.05%	5/9/2024 (Estimated)

Latest OPTN, BFRA, EVFM, and NBSE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	EVFM Evofem Biosciences	N/A	-$0.44	-$0.44	-$0.44	N/A	$4.84 million
3/7/2024	12/31/2023	OPTN OptiNose	-$0.10	-$0.09	+$0.01	-$0.09	$19.90 million	$19.87 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRA Biofrontera	0.13	1.26	1.13
EVFM Evofem Biosciences	N/A	0.13	0.10
NBSE NeuBase Therapeutics	N/A	2.87	2.87
OPTN OptiNose	N/A	0.60	0.55

Ownership

Institutional Ownership

Company	Institutional Ownership
BFRA Biofrontera	60.07%
EVFM Evofem Biosciences	0.22%
NBSE NeuBase Therapeutics	12.37%
OPTN OptiNose	85.60%

Insider Ownership

Company	Insider Ownership
BFRA Biofrontera	N/A
EVFM Evofem Biosciences	0.21%
NBSE NeuBase Therapeutics	13.90%
OPTN OptiNose	2.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRA Biofrontera	138	28.36 million	N/A	Not Optionable
EVFM Evofem Biosciences	35	53.96 million	53.85 million	Not Optionable
NBSE NeuBase Therapeutics	37	3.75 million	3.23 million	Not Optionable
OPTN OptiNose	132	112.65 million	110.17 million	Not Optionable

OPTN, BFRA, EVFM, and NBSE Headlines

Source	Headline
	Optinose to Present at Needham Virtual Healthcare Conference msn.com - April 7 at 9:30 AM
	OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago finance.yahoo.com - April 6 at 2:26 PM
	Optinose to Present at the Needham Virtual Healthcare Conference globenewswire.com - April 4 at 4:01 PM
	Michael F. Marino III Sells 15,059 Shares of OptiNose, Inc. (NASDAQ:OPTN) Stock insidertrades.com - March 20 at 7:32 AM
	Insider Selling: OptiNose, Inc. (NASDAQ:OPTN) Insider Sells 15,059 Shares of Stock marketbeat.com - March 19 at 1:24 PM
	Optinose, Inc.: XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps finanznachrichten.de - March 16 at 1:18 PM
	OptiNose granted FDA nod to expand labeling for sinusitis therapy msn.com - March 16 at 1:18 PM
	Bucks County's Optinose wins FDA approval for wider use of flagship product bizjournals.com - March 15 at 8:58 PM
	XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps globenewswire.com - March 15 at 3:34 PM
	Optinose primed for FDA ruling on Xhance that could 'reshape' its future bizjournals.com - March 13 at 8:17 PM
	US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results finance.yahoo.com - March 10 at 1:35 PM
	OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript seekingalpha.com - March 10 at 12:26 AM
	OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 8 at 12:56 PM
	OptiNose Full Year 2023 Earnings: EPS Beats Expectations finance.yahoo.com - March 8 at 7:55 AM
	OptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ... finance.yahoo.com - March 7 at 4:14 PM
	OPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023 investorplace.com - March 7 at 2:01 PM
	Optinose, Inc.: Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights finanznachrichten.de - March 7 at 10:19 AM
	Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights finance.yahoo.com - March 7 at 10:19 AM
	OptiNose reports mixed results; initiates Q1 and FY24 outlook msn.com - March 7 at 10:19 AM
	OptiNose: Q4 Earnings Snapshot washingtonpost.com - March 7 at 10:19 AM
	OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates zacks.com - March 7 at 9:16 AM
	Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights globenewswire.com - March 7 at 7:00 AM
	OptiNose's Earnings: A Preview benzinga.com - March 6 at 6:45 PM
	Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results globenewswire.com - February 29 at 4:40 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Biofrontera

NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Evofem Biosciences

NASDAQ:EVFM

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

NeuBase Therapeutics

NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

OptiNose

NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial